Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225Ac to B7-H3 (CD276) expressing tumors, including prostate, lung and other solid tumors. It has license and collaboration agreements with Protein Innovation, Inc., TRIUMF Innovations, Inc., and Eli Lilly. The company was formerly known as HotKnot Therapeutics, Inc. and changed its name to Aktis Oncology, Inc. in April 2020. Aktis Oncology, Inc. was incorporated in 2020 and is headquartered in Boston, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 4 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | $-72M | $-64M | $-74M | 43.6% | 336.9% | 44.9% |
| 2024 | $1M | $-50M | $-44M | $12M | 50.1% | - | 53.6% |
| 2023 | $0M | $-34M | $-29M | $-34M | 61.9% | - | 59.7% |
| 2022 | $0M | $-19M | $-18M | $-20M | 93.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 6.50 |
| Operating Revenue | 6.50 |
| Operating Expense | 81.18 |
| Research And Development | 67.45 |
| Selling General And Administration | 12.60 |
| Total Expenses | 81.18 |
| Operating Income | -74.68 |
| Total Operating Income As Reported | -74.68 |
| EBITDA | -72.36 |
| Normalized EBITDA | -72.36 |
| EBIT | -74.68 |
| Interest Income | 11.01 |
| Net Interest Income | 11.01 |
| Other Non Operating Income Expenses | -0.06 |
| Other Income Expense | -0.06 |
| Interest Income Non Operating | 11.01 |
| Net Non Operating Interest Income Expense | 11.01 |
| Pretax Income | -63.73 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -63.73 |
| Net Income From Continuing And Discontinued Operation | -63.73 |
| Net Income From Continuing Operation Net Minority Interest | -63.73 |
| Net Income | -63.73 |
| Net Income Common Stockholders | -63.73 |
| Net Income Including Noncontrolling Interests | -63.73 |
| Normalized Income | -63.73 |
| Diluted NI Availto Com Stockholders | -63.73 |
| Basic Average Shares | 52.52 |
| Diluted Average Shares | 52.52 |
| Reconciled Depreciation | 2.33 |
| Total Unusual Items | - |
| Total Unusual Items Excluding Goodwill | - |
| Gain On Sale Of Security | - |
| Depreciation Amortization Depletion Income Statement | 1.13 |
| Depreciation And Amortization In Income Statement | 1.13 |
| General And Administrative Expense | 12.60 |
| Other Gand A | 4.92 |
| Salaries And Wages | 7.68 |
| Depreciation Income Statement | 1.13 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Aktis Oncology, Inc.this co. | AKTS | $1.1B | -17.25 | -7.52 | 43.6% | -14.83 |
| Absci Corporation | ABSI | $1.1B | -9.94 | 6.04 | -60.8% | -10.95 |
| OPKO Health, Inc. | OPK | $1.1B | -4.88 | 0.87 | -17.8% | -27.38 |
| MannKind Corporation | MNKD | $1.1B | 185.49 | -21.31 | -11.5% | 26.79 |
| Savara Inc. | SVRA | $1.1B | -9.14 |
| 5.35 |
| -58.5% |
| -8.83 |
| Omada Health, Inc. | OMDA | $1.1B | -84.72 | 4.71 | -5.6% | -181.05 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.1B | 1916.51 | 77.56 | 4.0% | 28.56 |
| Collegium Pharmaceutical, Inc. | COLL | $1.1B | 16.86 | 3.51 | 20.8% | 4.10 |
| CONMED Corporation | CNMD | $1.1B | 22.48 | 1.02 | 4.6% | 10.49 |
| Peer Median | - | 5.99 | 4.11 | -8.5% | -2.36 | |